Signification of hypermethylated in cancer 1 (HIC1) as tumor suppressor gene in tumor progression

Cancer Microenvironment

Volumn 5, Issue 3, 2012, Pages 285-293

  Zheng, Jianghua ^a   Xiong, Dan ^a   Sun, Xueqing ^a   Wang, Jinglong ^a   Hao, Mingang ^a   Ding, Tao ^b   Xiao, Gang ^a   Wang, Xiumin ^a   Mao, Yan ^c   Fu, Yuejie ^d   Shen, Kunwei ^c   Wang, Jianhua ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

^c SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Epigenetic modification; HIC1; Tumor microenviroment; Tumor progression

Indexed keywords

CHEMOKINE RECEPTOR CXCR7; DNA; MICRORNA; SIRTUIN 1; TUMOR MARKER;

ARTICLE; CANCER STEM CELL; CARCINOGENESIS; CELL SURVIVAL; DNA METHYLATION; DNA MODIFICATION; EPIGENETICS; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE INACTIVATION; GENE STRUCTURE; GENE TARGETING; HIC1 GENE; HUMAN; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE;

EID: 84859497210     PISSN: 18752292     EISSN: 18752284     Source Type: Journal    
DOI: 10.1007/s12307-012-0103-1     Document Type: Article

References (82)

1. Wales MM et al (1995) p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med 1(6):570-577
2. Fleuriel C et al (2009) HIC1 (hypermethylated in cancer 1) epigenetic silencing in tumors. Int J Biochem Cell Biol 41(1):26-33
3. Jenal M, et al. (2010) Inactivation of the hypermethylated in cancer 1 tumour suppressor—not just a question of promoter hypermethylation? Swiss Med Wkly 140(w13106)
4. Chen WY et al (2003) Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrumofmalignant tumors. Nat Genet 33(2):197-202
5. Chen W et al (2004) Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis. Canc Cell 6(4):387-398
6. Briggs KJ et al (2008) Cooperation between the Hic1 and Ptch1 tumor suppressors in medulloblastoma. Genes Dev 22(6):770-785
7. Dehennaut V, Leprince D (2009) Implication of HIC1 (hypermethylated in cancer 1) in the DNA damage response. Bull Canc 96 (11):E66-E72
8. Boulay G, et al. (2011) Loss of hypermethylated in cancer 1 (HIC1) in breast cancer cells contributes to stress induced migration and invasion through beta-2 adrenergic receptor (ADRB2) misregulation. J Biol Chem
9. Foveau B, et al. (2012) Receptor tyrosyne kinase Epha2 is a direct target-gene of Hic1 (hypermethylated in cancer 1). J Biol Chem
10. Carter MG et al (2000) Mice deficient in the candidate tumor suppressor gene Hic1 exhibit developmental defects of structures affected in the Miller-Dieker syndrome. Hum Mol Genet 9(3):413-419
11. Guerardel C et al (2001) Identification in the human candidate tumor suppressor gene HIC-1 of a new major alternative TATAless promoter positively regulated by p53. J Biol Chem 276(5):3078-3089
12. Pinte S et al (2004) Identification of a second G-C-rich promoter conserved in the human, murine and rat tumor suppressor genes HIC1. Oncogene 23(22):4023-4031
13. Britschgi C et al (2006) Identification of the p53 family-responsive element in the promoter region of the tumor suppressor gene hypermethylated in cancer 1. Oncogene 25(14):2030-2039
14. Mondal AM et al (2006) Identification and functional characterization of a novel unspliced transcript variant of HIC-1 in human cancer cells exposed to adverse growth conditions. Cancer Res 66(21):10466-10477
15. Albagli O et al (1995) The BTB/POZ domain: a new proteinprotein interaction motif common to DNA-and actin-binding proteins. Cell Growth Differ 6(9):1193-1198
16. Stogios PJ et al (2005) Sequence and structural analysis of BTB domain proteins. Genome Biol 6(10):R82
17. Kelly KF, Daniel JM (2006) POZ for effect-POZ-ZF transcription factors in cancer and development. Trends Cell Biol 16(11):578-587
18. Pinte S et al (2004) The tumor suppressor gene HIC1 (hypermethylated in cancer 1) is a sequence-specific transcriptional repressor: definition of its consensus binding sequence and analysis of its DNA binding and repressive properties. J Biol Chem 279 (37):38313-38324
19. Ahmad KF et al (2003) Mechanism of SMRTcorepressor recruitment by the BCL6 BTB domain. Mol Cell 12(6):1551-1564
20. Ghetu AF et al (2008) Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer. Mol Cell 29(3):384-391
21. Deltour S, Guerardel C, Leprince D (1999) Recruitment of SMRT/ N-CoR-mSin3A-HDAC-repressing complexes is not a general mechanism for BTB/POZ transcriptional repressors: the case of HIC-1 and gammaFBP-B. Proc Natl Acad Sci U S A 96(26):14831-14836
22. Chen WY et al (2005) Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 123(3):437-448
23. Deltour S et al (1998) The carboxy-terminal end of the candidate tumor suppressor gene HIC-1 is phylogenetically conserved. Biochim Biophys Acta 1443(1-2):230-232
24. Stankovic-Valentin N et al (2007) An acetylation/deacetylation-SUMOylation switch through a phylogenetically conserved psiKXEP motif in the tumor suppressor HIC1 regulates transcriptional repression activity. Mol Cell Biol 27(7):2661-2675
25. Bertrand S et al (2004) Identification and developmental expression of the zebrafish orthologue of the tumor suppressor gene HIC1. Biochim Biophys Acta 1678(1):57-66
26. Deltour S et al (2002) The human candidate tumor suppressor gene HIC1 recruits CtBP through a degenerate GLDLSKK motif. Mol Cell Biol 22(13):4890-4901
27. Chinnadurai G (2007) Transcriptional regulation by C-terminal binding proteins. Int J Biochem Cell Biol 39(9):1593-1607
28. Shalizi A et al (2006) A calcium-regulated MEF2 sumoylation switch controls postsynaptic differentiation. Science 311(5763): 1012-1017
29. Geiss-Friedlander R, Melchior F (2007) Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol 8(12):947-956
30. Kanwal R, Gupta S (2011) Epigenetic modifications in cancer. Clin Genet
31. Morton RA Jr et al (1996) Hypermethylation of chromosome 17P locus D17S5 in human prostate tissue. J Urol 156(2 Pt 1):512-516
32. Eguchi K et al (1997) DNA hypermethylation at the D17S5 locus in non-small cell lung cancers: its association with smoking history. Cancer Res 57(21):4913-4915
33. Hayashi M et al (2001) Reduced HIC-1 gene expression in nonsmall cell lung cancer and its clinical significance. Anticancer Res 21(1B):535-540
34. Fujii H et al (1998) Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer. Oncogene 16(16):2159-2164
35. Kanai Y et al (1998) DNA hypermethylation at the D17S5 locus is associated with gastric carcinogenesis. Cancer Lett 122(1-2):135-141
36. Kanai Y et al (1999) DNA hypermethylation at the D17S5 locus and reduced HIC-1 mRNA expression are associated with hepatocarcinogenesis. Hepatology 29(3):703-709
37. Huang J et al (2000) High frequency allelic loss on chromosome 17p13.3-p11.1 in esophageal squamous cell carcinomas from a high incidence area in northern China. Carcinogenesis 21 (11):2019-2026
38. Eads CA et al (2001) Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 61(8):3410-3418
39. Koul S, et al. (2002) Characteristic promoter hypermethylation signatures in male germ cell tumors. Mol Cancer 1(8)
40. Rood BR et al (2002) Hypermethylation of HIC-1 and 17p allelic loss in medulloblastoma. Cancer Res 62(13):3794-3797
41. Rathi A et al (2003) Aberrant methylation of the HIC1 promoter is a frequent event in specific pediatric neoplasms. Clin Cancer Res 9 (10 Pt 1):3674-3678
42. Waha A et al (2003) Epigenetic silencing of the HIC-1 gene in human medulloblastomas. J Neuropathol Exp Neurol 62(11): 1192-1201
43. Waha A et al (2004) Analysis of HIC-1 methylation and transcription in human ependymomas. Int J Cancer 110(4):542-549
44. Nishida N et al (2008) Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology 47(3):908-918
45. Uhlmann K et al (2003) Distinct methylation profiles of glioma subtypes. Int J Cancer 106(1):52-59
46. Issa JP, Baylin SB, Herman JG (1997) DNA methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia 11(Suppl 1):S7-S11
47. Issa JP et al (1997) HIC1 hypermethylation is a late event in hematopoietic neoplasms. Cancer Res 57(9):1678-1681
48. Huffman DM et al (2007) SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 67(14):6612-6618
49. Stocklein H et al (2008) Detailed mapping of chromosome 17p deletions reveals HIC1 as a novel tumor suppressor gene candidate telomeric to TP53 in diffuse large B-cell lymphoma. Oncogene 27 (18):2613-2625
50. Tseng RC et al (2009) Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients. Neoplasia 11(8):763-770
51. Briones VR et al (2006) Mechanism of fibroblast growth factorbinding protein 1 repression by TGF-beta. Biochem Biophys Res Commun 345(2):595-601
52. Zhang W et al (2010) A potential tumor suppressor role for Hic1 in breast cancer through transcriptional repression of ephrin-A1. Oncogene 29(17):2467-2476
53. Foveau B et al (2012) The receptor tyrosine kinase EphA2 is a direct target gene of hypermethylated in cancer 1 (HIC1). J Biol Chem 287(8):5366-5378
54. Zhang B et al (2009) Requirement for chromatin-remodeling complex in novel tumor suppressor HIC1-mediated transcriptional repression and growth control. Oncogene 28(5):651-661
55. Jenal M et al (2009) The tumor suppressor gene hypermethylated in cancer 1 is transcriptionally regulated by E2F1. Mol Canc Res 7 (6):916-922
56. Valenta T et al (2006) HIC1 attenuates Wnt signaling by recruitment of TCF-4 and beta-catenin to the nuclear bodies. EMBO J 25 (11):2326-2337
57. Van Rechem C et al (2010) Differential regulation of HIC1 target genes by CtBP and NuRD, via an acetylation/SUMOylation switch, in quiescent versus proliferating cells. Mol Cell Biol 30 (16):4045-4059
58. Pateras IS et al (2009) p57KIP2: Kipping the cell under control. Mol Canc Res 7(12):1902-1919
59. Boulay G et al (2012) Loss of hypermethylated in cancer 1 (HIC1) in breast cancer cells contributes to stress-induced migration and invasion through beta-2 adrenergic receptor (ADRB2) misregulation. J Biol Chem 287(8):5379-5389
60. Van Rechem C et al (2009) Scavenger chemokine (CXC motif) receptor 7 (CXCR7) is a direct target gene of HIC1 (hypermethylated in cancer 1). J Biol Chem 284(31):20927-20935
61. Di Marcotullio L et al (2004) REN(KCTD11) is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma. Proc Natl Acad Sci U S A 101(29):10833-10838
62. Goodrich LV et al (1997) Altered neural cell fates andmedulloblastoma in mouse patched mutants. Science 277(5329):1109-1113
63. Ferretti E et al (2005) Hedgehog checkpoints in medulloblastoma: the chromosome 17p deletion paradigm. Trends Mol Med 11 (12):537-545
64. Wetmore C, Eberhart DE, Curran T (2001) Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Res 61(2):513-516
65. Spivakov M, Fisher AG (2007) Epigenetic signatures of stem-cell identity. Nat Rev Genet 8(4):263-271
66. Lee TI et al (2006) Control of developmental regulators by polycomb in human embryonic stem cells. Cell 125(2):301-313
67. Widschwendter M et al (2007) Epigenetic stem cell signature in cancer. Nat Genet 39(2):157-158
68. Ohm JE et al (2007) A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 39(2):237-242
69. Kalari S, Pfeifer GP (2010) Identification of driver and passenger DNA methylation in cancer by epigenomic analysis. Adv Genet 70 (277-308)
70. Saito K et al (2008) Aberrant methylation status of known methylation-sensitive CpG islands in gastrointestinal stromal tumors without any correlation to the state of c-kit and PDGFRA gene mutations and their malignancy. Canc Sci 99(2):253-259
71. Dumont N et al (2008) Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc Natl Acad Sci U S A 105(39):14867-14872
72. Polyak K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9(4):265-273
73. Finak G et al (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14(5):518-527
74. Qiu W et al (2008) No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet 40(5):650-655
75. Hellebrekers DM et al (2007) Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res 67 (9):4138-4148
76. Jing Y, et al. (2011) Epithelial-mesenchymal transition in tumor microenvironment. Cell Biosci 1(29)
77. Xia D et al (2012) Prostaglandin E(2) promotes intestinal tumor growth via DNA methylation. Nat Med 18(2):224-226
78. Ng EK et al (2009) MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. Br J Cancer 101(4):699-706
79. Claes B, Buysschaert I, Lambrechts D (2010) Pharmacoepigenomics: discovering therapeutic approaches and biomarkers for cancer therapy. Heredity (Edinb) 105(1):152-160
80. Lyko F, Brown R (2005) DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Canc Inst 97 (20):1498-1506
81. Zhou P, Lu Y, Sun XH (2012) Effects of a novel DNA methyltransferase inhibitor zebularine on human lens epithelial cells. Mol Vis 18(22-28)
82. Christman JK (2002) 5-azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 21(35):5483-5495